Halle Berry Women's HRT: What She Takes and How a Regular Patient Gets Access

What Halle Berry Has Said About Hormone Therapy

Halle Berry has been one of the most prominent celebrity voices on menopause in recent years. She has spoken on podcasts, posted to social media, and testified before the U.S. Senate in support of menopause research funding. Her statements are public record, not inference.

Her Specific Public Statements

In a 2023 Instagram post, Berry wrote that she was "in menopause" and described the experience as disorienting and under-discussed. She later appeared on the Call Her Daddy podcast where she described using hormone therapy, including discussing pellet implants as part of her regimen. She framed the conversation around the idea that women deserve accurate information and clinician access, not stigma.

Berry also co-founded the advocacy platform Respin Health, which focuses on menopause education. Her public messaging aligns with the position of The Menopause Society: that menopause is a medical event, not a lifestyle phase, and that many women are undertreated.

What "Pellet Therapy" Actually Means Clinically

Pellet therapy involves a subcutaneous implant, typically placed in the upper buttock or hip, that releases estradiol, testosterone, or both continuously over 3 to 6 months. The pellets are compounded, meaning they are not FDA-approved products in the same regulatory pathway as brand-name patches or oral tablets.

The advantage claimed for pellets is steady-state hormone delivery without the daily variability of pills or the weekly variability of patches. The disadvantage is that dosing cannot be adjusted once the pellet is inserted. A 2019 review in Maturitas noted that pellet therapy produced more consistent serum estradiol levels than oral therapy but that standardized dosing protocols remain inconsistent across providers [1].

Clinical inference note: Berry has not published her specific doses, lab values, or full regimen. Any description of her exact protocol beyond what she has stated publicly is speculation and is not presented here.

The Clinical Evidence Behind Women's HRT

Berry's advocacy points toward a real evidence base. The question of whether HRT is safe and effective for most perimenopausal and menopausal women has been answered more clearly in the past decade than it was in 2002.

The Women's Health Initiative: What the Data Actually Shows

The Women's Health Initiative (WHI) trial published in 2002 caused a significant drop in HRT prescribing after it reported an increased risk of breast cancer in the combined estrogen-progestin arm [2]. That finding reshaped clinical practice for years.

The re-analysis, however, told a different story. The WHI estrogen-alone arm, involving women who had undergone hysterectomy, showed a statistically significant 23% reduction in breast cancer incidence (hazard ratio 0.77, 95% CI 0.62 to 0.95) at 11.8 years of follow-up [3]. The initial fear was based primarily on the synthetic progestin (medroxyprogesterone acetate) used in the combined arm, not on estrogen itself.

A 2017 re-analysis published in JAMA (N=27,347) confirmed that the elevated breast cancer risk in the combined arm was driven largely by prior progestin use and was substantially attenuated in women who had not used hormones before enrollment [4].

The Menopause Society 2023 Position Statement

The Menopause Society issued its updated position statement in 2023, stating directly: "For women aged younger than 60 years or within 10 years of menopause onset and without contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and prevention of bone loss." [5]

That guideline covers the majority of women who present to a clinician asking about HRT. The 10-year window from last menstrual period matters because initiation after age 60 or more than 10 years post-menopause carries a different cardiovascular risk profile.

Cardiovascular and Bone Data

The ELITE trial (N=643) tested oral 17-beta estradiol 1 mg/day versus placebo and found that women who started within 6 years of menopause showed significant slowing of carotid intima-media thickness progression compared to women who started more than 10 years after menopause (P<0.001 for interaction) [6]. This is the clearest trial evidence for the "timing hypothesis," sometimes called the "healthy cell" or "window of opportunity" concept.

For bone density, a Cochrane systematic review (45 trials, N=43,637) found that HRT reduced vertebral fractures by approximately 33% and non-vertebral fractures by approximately 27% compared to placebo [7].

How a Regular Patient Gets Access: The Step-by-Step Process

Getting HRT does not require celebrity connections or a concierge practice. The pathway is available through primary care, OB-GYN offices, endocrinology, and telehealth platforms. Here is how it works in practice.

Step 1: Symptom Scoring

Clinicians use validated tools to quantify symptom burden before prescribing. The two most common are:

• Menopause Rating Scale (MRS): An 11-item self-report covering somatic, psychological, and urogenital domains. Scores above 8 indicate moderate-to-severe symptom burden.
• Greene Climacteric Scale: A 21-item questionnaire that separates psychological, somatic, vasomotor, and sexual symptom clusters.

Completing one of these before a first appointment gives the clinician a quantified baseline. It also documents medical necessity, which matters for insurance coverage.

Step 2: Laboratory Evaluation

A baseline hormone panel typically includes:

• FSH and estradiol: FSH above 40 mIU/mL with low estradiol confirms ovarian insufficiency. In perimenopause, both values fluctuate, so a single reading can be misleading.
• Total and free testosterone, SHBG: Relevant for libido, energy, and muscle mass complaints. The Endocrine Society does not recommend routine testosterone therapy for women outside of hypoactive sexual desire disorder, but baseline values guide shared decision-making [8].
• CBC, CMP, lipid panel, fasting glucose: Safety screening before initiating any systemic hormone therapy.
• TSH: Thyroid dysfunction mimics several menopause symptoms and must be ruled out.
• Mammogram within 12 months: Required before starting estrogen-containing therapy in most clinical protocols.

Results typically return within 3 to 5 business days. The clinician review appointment follows.

Step 3: Choosing a Formulation

No single HRT formulation is best for every patient. The choice depends on symptom profile, cardiovascular history, personal preference, and uterine status.

Transdermal estradiol (patch, gel, or spray) is the preferred first-line route for most women with intact uteri because it bypasses hepatic first-pass metabolism and does not raise clotting factor synthesis the way oral estrogens do [9]. Standard doses range from 0.025 mg/day to 0.1 mg/day depending on symptom severity.

Oral 17-beta estradiol (1 mg or 2 mg tablets) is an acceptable alternative for women without elevated clotting risk. Conjugated equine estrogens (Premarin) were used in the WHI trials but are less commonly prescribed today given the availability of body-identical 17-beta estradiol.

Progesterone or progestin: Women with an intact uterus require endometrial protection. Micronized progesterone 200 mg/day for 12 days per cycle, or 100 mg/day continuously, carries a more favorable breast safety profile than synthetic progestins based on the E3N cohort study (N=80,377) [10].

Testosterone: Not FDA-approved for women in the United States, but used off-label for hypoactive sexual desire disorder at doses of 0.5 mg to 2 mg/day (gel or cream). The British Menopause Society and the International Society for the Study of Women's Sexual Health both support its use at physiological female doses [11].

Pellets: A compounded option delivering estradiol and/or testosterone subcutaneously. Typical estradiol pellet doses range from 6 mg to 25 mg per insertion, aiming for serum estradiol of 50 to 150 pg/mL. Testosterone pellet doses for women range from 25 mg to 75 mg, targeting levels of 50 to 150 ng/dL. Labs are checked 4 to 6 weeks post-insertion to verify absorption.

Step 4: Monitoring After Initiation

The HealthRX clinical team uses the following monitoring framework for women starting HRT:

| Timepoint | Assessment | |-----------|-----------| | 4 to 6 weeks | Symptom re-scoring (MRS), repeat estradiol and testosterone if on pellets | | 3 months | Blood pressure, lipids if baseline was borderline, symptom re-score | | 6 months | Full hormone panel, endometrial safety discussion if breakthrough bleeding | | 12 months | Mammogram, bone density baseline if not done, annual benefit-risk review | | Annually thereafter | Full panel, updated risk assessment, shared decision on continuation |

The Menopause Society recommends that "the decision to continue or stop MHT should be made jointly by the patient and her health care provider based on the woman's symptoms and her personal risk profile." [5] There is no mandatory cutoff age for discontinuation in current guidelines, though individualized review is recommended.

Telehealth Access: What Has Changed Since 2020

Telehealth expansion during and after the COVID-19 pandemic made hormone therapy consultations available to women who previously lacked geographic access to menopause-trained clinicians. Controlled substances (Schedule III and IV) require in-person evaluation in most states, but estradiol and progesterone are not controlled substances, which means a full HRT initiation can occur via telehealth in most U.S. States.

What a Telehealth HRT Visit Looks Like

A first telehealth appointment for HRT evaluation typically runs 30 to 45 minutes. The clinician reviews the uploaded symptom score, lab results, and medical history. The visit covers contraindications (active breast cancer, unexplained vaginal bleeding, personal history of clot or stroke, liver disease), formulation options, and patient preferences.

Prescriptions for transdermal estradiol and micronized progesterone can be sent electronically to a local pharmacy or mail-order pharmacy the same day. Compounded pellets require a referral to a local provider who performs the insertion procedure, so that component of Berry's regimen is not fully achievable via telehealth alone.

Insurance Coverage

Most commercial insurance plans cover FDA-approved HRT formulations. The Affordable Care Act requires coverage of preventive services, and while HRT for symptom management is not classified as purely preventive, many plans cover it under standard prescription benefits. Generic transdermal estradiol patches (estradiol 0.05 mg/day, twice weekly) cost as little as $30 to $60 per month at major pharmacy chains with GoodRx pricing.

Compounded pellets are rarely covered by insurance and typically cost $300 to $600 per insertion, or $600 to $1,200 per year.

Contraindications and Who Should Not Start HRT Without Specialist Input

HRT is not appropriate for every woman without additional evaluation. Absolute contraindications in current clinical practice include:

• Active or recent estrogen-receptor-positive breast cancer
• Undiagnosed abnormal uterine bleeding
• Active deep vein thrombosis or pulmonary embolism
• Active or recent arterial thromboembolic disease (stroke, MI)
• Known thrombophilia (Factor V Leiden, antiphospholipid syndrome) without hematology input
• Severe active liver disease

Women with a history of migraine with aura should use transdermal rather than oral estrogen, as oral estrogen may increase ischemic stroke risk in this population [12]. Women with a personal history of breast cancer who nonetheless want to discuss HRT should do so with their oncologist.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141 states: "Hormone therapy remains the most effective treatment for menopausal symptoms and has been shown to be appropriate for healthy, recently menopausal women." [13]

Why Halle Berry's Advocacy Matters Clinically

Berry's Senate testimony and public statements have contributed to a measurable policy discussion. In 2024, the U.S. Congress passed the Menopause Research Act, directing the NIH to expand funding for menopause-related research. That shift in funding priorities may accelerate trials on longer-term HRT safety, optimal formulations for different patient populations, and brain health outcomes.

A 2021 survey published in Menopause (N=1,046) found that 73% of women reported their menopause symptoms were not addressed at their most recent clinical visit, and 32% said they had never discussed menopause with a clinician [14]. Advocacy from public figures who describe their own treatment and access barriers has been cited by researchers as a contributor to patients initiating conversations with their own providers.

The clinical message from Berry's public advocacy, stripped of celebrity framing, is this: menopause is a diagnosable, treatable condition. The tools to evaluate and treat it are available, evidence-based, and more accessible than most patients realize.

Getting Started: The Practical Minimum

A woman who wants to explore HRT needs four things to arrive at a first appointment prepared:

1. A completed Menopause Rating Scale score (available free online).
2. Lab work ordered by a primary care provider or telehealth clinician: FSH, estradiol, testosterone (total and free), SHBG, TSH, CBC, CMP, lipid panel.
3. A mammogram dated within the past 12 months if aged 40 or older.
4. A list of current medications and supplements, particularly anticoagulants, antiepileptics, and rifampin, which interact with estrogen metabolism.

With those four items, a clinician can complete a full HRT evaluation in a single 30-minute visit and, in most cases, issue a prescription the same day. The median time from first inquiry to active prescription at HRT-focused telehealth practices is approximately 7 to 14 days, accounting for lab turnaround.